KEY NOTE SPEAKERS

  • Anna Prokůpková

    Policy & Project Officer

    Association of European Cancer Leagues (ECL)

  • Axel Boehnke

    Director Market Access Europe North

    PTC Therapeutics

  • Johan Holmström

    Global Pricing and Market Intelligence, Dental Implants

    Dentsply Sirona

  • Jörg Mahlich

    Head of Health Economics and Outcomes Research

    Janssen pharmaceutical

  • Ryotaro Ishikawa

    Global Market Access Director

    Novartis

  • Santiago Moreno

    Senior HEOR Manager

    Servier

  • Sebastian Gensior

    Managing Director

    Global Health Access Solutions

  • Wendy R. Jory

    Head of Global Pharma Pricing Strategy

    GlaxoSmithKline

  • Alan Crowther

    General Manager, Global Pricing & Access

    Eversana

  • Ruven Remo Eul

    Director, Life Sciences

    HighPoint Solutions

  • Fabrizio Gianfrate

    Professor of Health Economics

    University of Ferrara, Luiss Business School Rome, Italy

 

Pricing in a complex ecosystem  

dealing with transparency, collaborative relationships and smart data

 

The 9th annual EPP Life Sciences Pricing Forum will provide you with the latest knowledge on pricing trends, industry best-practices and will equip you with the tools necessary to empower your success. The theme of the forum will orbit around: Pricing in a complex ecosystem – dealing with transparency, collaborative relationships and smart data.

Our forum will enable you to make connections with over 100 industry leaders, share pioneering content and discuss the latest practices impacting pricing in the complex Life Sciences’ ecosystem. We will discuss new pricing strategy, effective collaboration with payers and other stakeholders, usage of data and technology to optimise pricing strategy, market access models, price policy and innovative pricing tools.

You will get access to exclusive content, 15+ expert presentations, 10+ case studies, 4+ workshops, 2+ Roundtable discussions, 2+ panel sessions and an incredible and entertaining evening event tailored to facilitate networking between Life Sciences industry leaders!

 

If you would like to share your knowledge on this upcoming forum, please contact our Conference Producer: camila.rios@pricingplatform.eu

or our Learning Development & Partner Relationships Manager: britt.dejager@pricingplatform.eu

You can also reach us at: +32(0)473.71.76.69

Pre-order the brochure now and have it sent to you as soon as it is ready. Just fill in your details when clicking the download brochure button.

 

 

 

Are you an influencer or specialized in pricing based on AI, machine learning – or agile pricing strategies in a digital world? we want to hear from you !

If you would like to contribute to this unique forum,
please contact Camila Rios at Camila.rios@pricingplatform.eu

         

The 8th EPP Life Sciences Pricing Forum was a big success in 2018!
Relive it now.

 

 

 


If you would like to be part of this amazing forum next year : please contact us:
camila.rios@pricingplatform.eu or  britt.dejager@pricingplatform.eu or just give us call +32(0)473.71.76.69 


5 reasons why you should attend the EPP Life Sciences Pricing Forum in 2019 

  1. You will acquire the latest knowledge on pricing trends, industry best-practices and the tools necessary to empower your success.
  2. 100+ senior industry leaders come together for exclusive keynote presentations, innovative workshops, breakouts on Pharma and MedTech, roundtable discussions and unrivaled networking to engage in high level discussions that will shape the future of pricing and market access in Life Sciences
  3. The forum agenda is created together with key industry influencers to include the most relevant and up-to-date content
  4. 18+ Speakers delivering interactive workshops, roundtables, panel discussions and ground-breaking presentation
  5. Pharma & MedTech Breakouts: Discuss, learn and challenge both strategic and tactical topic

Who will be attending?

Every year 100+ medtech and pharma industry delegates gather to discuss and reflect on the latest pricing and market access trends. The goal is to provide you with knowledge about best business practices and offer you a chance to meet world’s best experts in pricing and profit optimisation.

The EPP Life Sciences Pricing Forum brings together leading practitioners and experts to discuss, reflect, network and share. The forum is tailored for key stakeholders such as: Pricing, Reimbursement, Market Access, Commercial, Marketing and Sales Directors and VPs, CEOs and General Managers.

Please do not hesitate to contact us if you would like to get more information: camila.rios@pricingplatform.eu 

 


 

This is an event you must attend!

  • 1 BUILD RELATIONSHIPS

    With more than 1000 minutes of network opportunity, you have plenty of time to connect with pricing colleagues from all over Europe.

  • 2 DISCUSS

    We stimulate an atmosphere of discussion and interaction, the best way to learn.

  • 3 LEARN FROM THE BEST

    A carefully selected speaking team of top pricing professionals, all active within your industry. No general talk, but only to-the point and useful presentations.

  • 4 REFLECT & PRACTICE

    Reflect on your key priorities and how to make it really happen !  Translate your key learnings into real change.

THE PROGRAMME

We are working on the upcoming program 2019.

If you want to keep updated, please request the brochure (see top right in navigation).  As soon as the new brochure is available, we will send you the program !

October 15th 2019
Registration and networking coffee Hosts - EPP
Welcome Pol Vanaerde, President - - EPP
Session 1: Collaborative pricing in the increasingly transparent Life Sciences industry ecosystem ------------------------------------------- - -------------------------------------------
WHO’s resolution: greater transparency and fairer prices
  • WHO is facilitating countries’ information sharing to improve transparency of prices
  • Impact of increased transparency of research costs, development and production of medicines on global health
  • What is a “fair price”?
Hear about the EURIPID Initiative and understand the real impact in the Life Sciences industry
  • An in-depth analysis of current landscape of world’s push for transparency in pricing
  • Understand how EURIPID could radically change the way pricing strategy is defined
  • Other initiatives supporting transparency and collaborative pricing
  • Best-practices for collaborative pricing between stakeholders
Applying innovative insurance solutions to help future proof healthcare systems
  • Understanding the current public health systems challenges to fund future high-price medicines
  • Explore innovative insurance solutions to allow higher penetration of this strategy and tackle the issue
  • Discuss how learning from the financial sector can disrupt healthcare insurance via a sandbox approach
Interactive Panel Session: Understanding the implications of an increasingly transparent and interconnected environment
  • Understand how consolidation and acquisition of private and public institutions is impacting the industry and increasing transparency and communication between parties
  • How can you drive collaboration between parties and unite all healthcare stakeholders
PHARMA MEDTECH
Pricing Ecosystem game changer: International Reference Pricing, what will happen if the US joins?

  • Understand the current landscape of medicine pricing in the United States of America under Donald Trump’s administration push for transparency and reduced costs
  • Analyse what would happen if the International Pricing Index model for Medicare Part B passes
  • In depth understanding of consequences for global pricing in the industry if the United States joins IRP, and how can this impact European pricing strategy
The pathway towards a more sustainable healthcare system

  • Understand the current increasingly-challenging European situation, dilemmas, certainties and actions to take
  • Forecast of the healthcare system and potential actions to take to increase sustainability through innovative pricing strategies
  • The trend towards refurbished medical technology material, what does this mean for the industry?

 

Audience Polling Lunch – Join the group with the same topic of interest to discuss over lunch and enjoy casually chatting with other industry players over a delicious lunch.

Session 2 · Technology, SmartData and AI changing the pricing function in Life Sciences ------------------------------------------- - -------------------------------------------
Break-out
PHARMA MEDTECH
Case Study: The role of advanced analytics technologies in considering pipeline asset price strategies

  • Understand how incorporating advances analytics technologies in pharma can influence pricing strategy

Case study that demonstrated the mentioned

Excels and calculators are done, moving over to pricing apps

  • Discussing the current technology influenced landscape
  • Digitalization of pricing strategy and models, and how to effectively achieve this within an organization
  • Real case study on successful digitalization of pricing model into a mobile app
Assessing Data Sources for medicine price studies with the Pharmaceutical Pricing and Reimbursement Policies, a WHO Collaborating Centre

  • Learn how to assess the feasibility of medicine price data sources
  • Explore a framework to guide the selection of most appropriate price data sources for pharmacoeconomic research
  • Hear the results and the conclusions of the study to guide you into the correct selection of data sources for medicine price studies
Using transactional data to clearly define customer groups and optimize pricing

  • Understand how using data to comprehend customer trends and buying behaviour can build a strong pricing strategy
  • Comprehend the Usage of Breakeven and Price Dispersion to find the optimal price points for each segment
  • Listen to applicable learnings for pricing strategy optimization
Case Study: Using European Data Sources to optimise pricing strategy

  • Learn how to identify reliable and standardize data sources across Europe
  • Listen to a case study on how using these sources can help in defining the best pricing strategy and maximising profit
Roundtables Discussions

  • Applying technology to reduce pricing cycle process
  • Sharing of best practices of technology application to the pricing strategy
  • Using SmartData to demonstrate the value of your product effectively
Roundtables Discussion

  • Applying technology to reduce pricing cycle process
  • Sharing of best practices of technology application to the pricing strategy
  • Using SmartData to demonstrate the value of your product effectively

 

Artificial Intelligence impacting pricing function in Life Sciences, defining the path for tomorrow
  • Current landscape of AI in other industries and how this has helped the pricing function
  • Addressing today’s limitations for Life Sciences Industry – using algorithms is not artificial intelligence
  • Understand how to apply data and analytics to increase pricing models efficiency
  • Case Study of application
Blockchain technology for value-based payments in healthcare, is this a reality?
  • How is blockchain affecting the global Life Sciences pricing function and how to use it to benefit all parties
  • Understand how blockchain technology can be used to create a medical information infrastructure while sharing it in an immutable and synchronised manner
  • How to reduce the pricing cycle length by removing administrative processes with the usage of smart contracts
Transforming Big Data into Smart Data to increase operational efficiency
  • Learn how to obtain, manage and analyse available industry mass data to curated insightful information to increase operational efficiency in the pricing process
  • Understand the importance of incorporating data analytics in the early pricing stages to increase likelihood of successful pricing implementation in the future
October 16th 2019
Enjoy a good cup of coffee
Session 3: Innovative Pricing Models in Life Sciences ------------------------------------------- - -------------------------------------------
Exploring new pricing models to deal with margin tightening and transparency demands from payers
  • Increased transparency pleas are fuelling price pressure – how to use solution-driven pricing models in response
  • The importance of aligning price with value to create options for innovative pricing models and understanding how to communicate this accordingly
  • Capturing a price-premium through risk-sharing, monetizing of innovation, flexible leasing and others…
A pragmatic approach to outcome-based pricing in Life Sciences
  • Trial and error – take a look at unsuccessful value-based pricing strategies and understand the causes of failure – how does value based relate to outcome based?
  • Explore outcome-based pricing, how to implement effective plans for short term and long-term accomplishment and accelerate the transition
  • Case study of successful implementation
How to cope with price erosion throughout the product life cycle
  • Understand the specific pricing challenges that arise in each stage of the product life cycle and how to address these
  • Explore how to deal with competitive and pricing pressure to reduce price erosion and increase profitability
  • Comprehend strategies to stay profitable with Generic/biosimilar drug market entry
PHARMA MEDTECH
Case Study: Hear about one of the most successful Orphan Drug Launches

  • Explore how a new approach to pricing a rare disease drug led to a successful and lucrative launch
  • In-depth analysis of the most successful orphan drug launch by Biogen explaining implementation, management, reimbursement and outcomes
  • Understand main takeaways and applicable learnings
Case Study: MedTech’s shift from selling features to selling a service

  • Best practise operators shifting the focus from selling features to selling value through service, how to do it and how to communicate it to stakeholders effectively
  • Re-structuring organizations from price focus to quality focus
  • Understand the external and internal perspectives of the value-based approach with a real-life case study
Case Study: The role of Cost-Effective Analysis in incentivizing innovation to derive an appropriate price for innovative drugs

  • In depth analysis of current conventional CEA for reimbursement decisions landscape causes, consequences and potential solutions
  • Learn an approach to value-based pricing aligning the incentives for innovation with the needs of patients with examples
  • Conclusions of case study
Case Study: Implementing subscription-based pricing in MedTech

  • Expanding service offerings whilst maintaining profitability
  • Early development of subscription-based pricing, how to effectively apply it throughout the pricing cycle and its consequences
  • Learn about how to successfully implement this payment model with a real case study
Interactive Campfire Storytelling Session

 Be ready to share your own pricing experiences with others!

Be ready to discuss the topics covered in the conference so far, and how you plan to use the knowledge gained into your role.

Interactive Campfire Storytelling Session

 Be ready to share your own pricing experiences with others!

Be ready to discuss the topics covered in the conference so far, and how you plan to use the knowledge gained into your role.

Lunch & Networking

Join the group with the same topic of interest to discuss over lunch and enjoy casually chatting with other industry players over a delicious lunch.

Speaking value: Understand how to communicate value as the decisive factor for procurement
  • Discover how to stay away from price as the decisive factor for purchase and shift focus to true incentive behind procurement outcome
  • Explore the assessment process of proposals and/or bids, and how it is analysed to determine the aftermath
  • Case study of successful methodology implementation
Addressing the current global landscape of tendering, overcoming its challenges and best approach to effective tendering
  • Analysis of the current global landscape of tendering and the push towards tendering as the preferred procurement process for drugs
  • Overcoming price as the main decisive factor in a RFP, how to communicate value through the tendering process
  • How to solve these challenges with technology and data
Aligning global and local resources towards effective tendering
  • How to reduce the time of the tendering cycle through effective tendering management
  • Understand how to motivate the team to work on tender management
  • Comprehend how to evaluate the ratio of return of investment of the tendering process
Pricing, Market Access and HEOR cooperating together towards a unified goal

 

  • Increasing operational effectiveness through early incorporation of market access and HEOR in the pricing process
  • Case study to demonstrate a successful approach and how to apply this within organization
Interactive Panel Session: Addressing the claim: When sellers say better value, payors hear lower price
  • Constructive discussion between sellers and payors to increase understanding of the drivers behind decision-making
  • Cooperate together to define what does good value mean and how to achieve successful collaboration

Contact Forum Producer

Camila Rios

PRE FORUM WORKSHOPS

Interested in delivering a Workshop ?

This can be your space to tell the industry about your innovative solutions and products.
Contact Camila Rios, e: Camila.rios@pricingplatform.eu

KEY NOTE SPEAKERS

If you would like to join the speaker faculty, please contact Camila Rios : Camila.rios@pricingplatform.eu

Anna Prokůpková

Policy & Project Officer

Association of European Cancer Leagues (ECL)

Anna is a Policy & Project Officer at the Association of European Cancer Leagues (ECL) responsible for advocacy in the areas of equal access to cancer treatments and patient support. With the ECL Access to Medicines Task Force, Anna works on affordability, fair pricing, and accessibility of cancer medicines. Increased collaboration between European countries in pricing and reimbursement and transparency in medicines prices are key focus of her work. Anna also acts as a liaison for the MEPs Against Cancer (MAC) Interest Group at the European Parliament. Outside of ECL, Anna is a member of the Alliance for responsible R&D and Affordable Medicines, ESMO Patient Advocacy network, Young Gasteiners programme and the European Health Parliament.

Axel Boehnke

Director Market Access Europe North

PTC Therapeutics

Axel Boehnke is a Health Economist, with a master’s degree on Health and Medical Management, currentlyresponsible for EU North as Director Market Access at PTC Therapeutics. Working in pharmaceutical industry for over 15 years allowed him to develop a strong market access skill set with proven track record, executed in Oncology, Autoimmune Diseases, (Ultra) Orphan Diseases, Hepatology, anti-virals, from Humira-franchise business at Abbott, in Servier and deep diverse Biotech Experience. He is a member of the Germany Society of Market Access and the German Society of Health Economics. Before joining the industry, he worked on a German payer organisation.

Johan Holmström

Global Pricing and Market Intelligence, Dental Implants

Dentsply Sirona

Johan Holmström has long and broad experience from leading innovations in various roles in product development, marketing and pricing management. He is currently heading up a team responsible for global strategic pricing of a portfolio with hardware products, software solutions and services. In this role he is leading market intelligence and pricing strategies but also activities to turn them into sustainable business through innovative go-to market and commercialization models.

Johan holds a MSc in engineering from the Royal Institute of Technology, Stockholm and has continued his lifelong learning with additional studies in marketing and business administration.

Jörg Mahlich

Head of Health Economics and Outcomes Research

Janssen pharmaceutical

Jörg Mahlich is head of Health Economics and Outcomes Research at Janssen pharmaceutical companies of Johnson and Johnson in Germany. In addition, he is lecturer of Health Economics at the Economics Department of the University of Vienna and research affiliate at the Düsseldorf Institute for Competition Economics (DICE) of the University of Düsseldorf, Germany. Previous to that he hold different positions in industry and consulting in Austria, Germany, and Japan. He is interested in global pharmaceutical economics and policy. Jörg graduated in economics from the University of Kiel, Germany and holds a doctoral degree in economics from the University of Vienna, Austria.

Ryotaro Ishikawa

Global Market Access Director

Novartis

Ryotaro Ishikawa, MD MBA, with more than 20 years of experience in healthcare industry, is dedicated to test and trial innovative solutions for customers, patients and stakeholder in different geographies. International executive passionate about building high performance teams in Marketing and Sales, Market Access, HEOR in emerging markets.

Experienced in driving value/evidence generation strategy within a cross-functional matrix for HTA Markets including Europe, Latin-America and Asia.

 

Santiago Moreno

Senior HEOR Manager

Servier

Santiago Moreno is an HEOR/HTA professional with +10 years’ experience in the industry and public sector. Over the past decade, Santiago has held various HEOR/HTA positions, most notable at Novartis and Roche. In his current position, Santiago is responsible for leading the Global HEOR/HTA strategy of the oncology franchise at Servier (Paris). His primary focus is ensuring that the evidence package best supports affiliates in their pricing and reimbursement negotiations. Recently, he led the first Novartis submission to EUnetHTA (Rydapt®) and published a number of policy proposals in HTA/payer topics. Santiago holds a Phd in Medical statistics (University of Leicester,UK).

Sebastian Gensior

Managing Director

Global Health Access Solutions

Sebastian is the managing director of Global Health Access Solutions, where he provides clients with market insights and go-to-market strategies. Over the past seven years, he held multiple market access and health policy positions in the pharmaceutical industry, most notably at Roche and Edelman. He has supported pharmaceutical and medical devices clients in understanding healthcare markets around the world and was actively involved in healthcare reforms. Sebastian is constantly exploring innovative pricing and insurance solutions and bringing them to the market.

 

He holds a Bachelor in European Public Health from the University of Maastricht.

 

Wendy R. Jory

Head of Global Pharma Pricing Strategy

GlaxoSmithKline

Wendy R. Jory, MBA, Ph.D. is Head of Global Pharma Pricing Strategy at GlaxoSmithKline. She has over 20 years of diverse experience in biopharma spanning R&D, sales, product development, market access and commercial analytics. Her current position focuses on commercial strategy development for medicines in the early pipeline.

 

Dr. Jory earned her doctorate in Microbiology and Molecular Genetics from Emory University School of Medicine following a master’s degree in Chemistry from the College of William & Mary.  She earned her MBA from Kellogg School of Management.

Alan Crowther

General Manager, Global Pricing & Access

Eversana

Alan Crowther is President of Global Markets of Alliance Life Sciences, responsible for overseeing the Global Pricing solutions for Alliance. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm focused on life sciences analytical software; Vice President at Capgemini; Co-founder and Officer at Adjoined Consulting, where he ran the Life Sciences practice and was part of the leadership of the venture-backed company and helped drive it to a successful $200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that. He is a graduate of Princeton University.

 

Ruven Remo Eul

Director, Life Sciences

HighPoint Solutions

Ruven is a Director within the European Life Sciences team based out of Zug, Switzerland responsible for project oversight and delivery, resource management and solution development in the areas of Pricing, Contracting and Tendering. Ruven brings a background of industry experiences in large pharma from companies such as Pfizer and BMS where he worked in Commercial roles with a large focus on leading cross functional Tendering teams for Pfizer in Germany. While at HighPoint Solutions, Ruven has worked with emerging, mid-tier and large pharma on various Tendering and Contracting programs from policy and process assessments, outsourcing of business functions, software vendor evaluations and implementation of global programs. Additionally, Ruven has conducted the industry’s first Benchmarking Study on Tendering issuing 4 reports presenting the benchmarking results and developed HighPoint’s Tender Data Service THOR focusing on supporting the awareness & planning phase of Tendering while building Competitive and Pricing Intelligence. In parallel, Ruven has also worked deeply in global commercial effectiveness programs.

Fabrizio Gianfrate

Professor of Health Economics

University of Ferrara, Luiss Business School Rome, Italy

Phd and Masters in Health Economics (Rome, Stockholm, York). Master in Economic Journalism.

Full Professor of Health Economics, Market Access Consultant, Columnist. Ex-payer as AIFA member (pricing and reimbursement committee), Regional HTA Committees member (several Regions), Director at Ministry of Health (appointed), General Manager and Vice President of GSK Foundation Italy and of Angelini Foundation, several director roles in pharmaceutical industries, secondments in UK and US.

Past: Director of several magazines on healthcare and pharma, formers member of Farmindustria, Assobiotech, CENSIS, EFPIA, Federfarma.
Actual: Board Member of Italian Society of Pharmacoeconomics and Ethicals and Italian society of Healthcare studies).
Author of more than 700 articles and 7 books.

TESTIMONIALS

Fresenius-Kabi SwissBioSim

Sue Caleo-Naeyaert, Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

“This is a great conference which covers most pricing topics with a decent amount of detail. Anyone can benefit from this conference no matter how experienced”

Ian Tidswell

Ian Tidswell, Founder and Lead Consultant at een Consulting GmbH

The EPP Life Sciences Pricing Forum is a unique event for learning about the latest pricing challenges and techniques to address them, due to the deep experiences and skills of the participants and speakers

BTG

Giuseppe Monita , Senior Manager, Customer Services Contracts & Tendering EMEA at BTG

“Exciting & energetic meeting where it is possible to learn, share & discuss best practices and new ideas on hot topics regarding pricing & tendering” 

Cogentia Healthcare Consulting

David Alderson, Director at Cogentia Healthcare Consulting

“A good event for catching up, great networking and opportunity to share current thinking and best practice” 

Tefen Management Consulting

Chiara Garavaglia, Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation at Tefen Management Consulting

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”

Sue Caleo-Naeyaert

Sue Caleo-Naeyaert , Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

“This is a great conference which covers most pricing topics with a decent amount of detail.   Anyone can benefit from this conference no matter how experienced”

 

Henderson Azevedo

Henderson Azevedo, Global Pricing Oncology at Bayer

“A highly recommended forum for pricing professionals”

Alan Crowther

Alan Crowther, President, Global Markets at Alliance Life Sciences Consulting Group

“The 7th EPP Life Sciences Pricing Forum was the 3rd in a row that Alliance Life Sciences attended.  This year’s conference was the best yet in content. Participants come prepared to learn, share and together they helped shape the trends in our industry. The forum on the shores of Lake Geneva at the foot of the Alps is also the best locale you can imagine for a thought-provoking, content-rich conference. What a great atmosphere!”

Chiara Garavaglia

Chiara Garavaglia, Partner, Global Leader at Tefen Management Consulting

“In my experience, EEP is the only existing opportunity to discuss at 360 degrees about Pricing, involving both pharmaceutical and med tech stakeholders”

BD

, at

Baxter Healthcare

, at

Fresenius

, at

GSK

, at

Novo Nordisk

, at

Pfizer

, at

Philips Healthcare

, at

Cardinal Health

, at

Eisai

, at

Alcon

, at

Bristol-Myers Squibb

, at

Bracco Imaging

, at

Creative Ceutical

, at

Ferring

, at

Galderma

, at

GE healthcare

, at

Janssen

, at

Leica microsystems

, at

LFB

, at

Liva Nova

, at

Menarini

, at

NHS

, at

Novartis

, at

RIZIV

, at

Sanofi Aventis

, at

Shire

, at

Smith&Nephew

, at

Terumo

, at

TEVA

, at

UCB

, at

Tillots

, at

Meet pricing decision makers from:

VENUE

This year the 9th EPP Life Sciences Pricing Forum will take place in the Munich Airport Marriott Hotel.  The Munich Ariport Marriott Hotel is a beautiful venue located in a small relaxing town next to Munich.  The hotel is just a few minutes away from the airport and can be easily reached by a shuttle bus.

 

Address: Alois Steinecker Strasse 20, Freising 85354 Germany

 

CONTENT

Biosimilar pricing in Europe

When a biosimilar enters the market, the reference drug tends to drop in price in the face of competition, whether through internal or external reference pricing or health technology assesment. 

How to eat the value based procurement elephant ?

Procurement in the health care sector is clearly moving towards procurement of “Value”. In this context, it needs no saying Value-based Procurement will be high on the agenda of both health care providers and suppliers for at least the next few years.

How advanced analytics can help spot price optimization opportunities for a large portfolio of products across different markets

How advanced analytics can help spot price optimization opportunities for a large portfolio of products across different markets

by Halima Benghabrit, Global Pricing Director, Sanofi

Alternative pricing models for the future – Analysis of alternative pricing models such as pay for performance, risk sharing and subscriptions

Alternative pricing models for the future – Analysis of alternative pricing models such as pay for performance, risk sharing and subscriptions

by Finn Ziegler, Director, Global Patient Access, LEO Pharma

New types of contracts to obtain a fair reimbursement of your products

New types of contracts to obtain a fair reimbursement of your products

by Youssef Mamour – CPM, EMEA Pricing Director, Getinge

Download your content here !

We hope you enjoy the content.

EPP PARTNERSHIPS

For more info please contact Britt.dejager@pricingplatform.eu

REGISTRATION

. EPP Members benefit from our preferred membership rates – contact Britt Dejager
. Not yet a member ? Discover all EPP member benefits here 
• Once a registration is completed, tickets are transferable but never refundable. This applies to payments after invoice as well.

SAVE MONEY WITH THE SUPER EARLY BIRD TICKETS! VALID UNITL JULY 26!

FULL CONFERENCE PASS

1595
Super Early Bird
YOU JUST SAVED € 400
Access to workshops
Access to 2 forum days
Access to evening event
PDF presentations after event

BUY 2 GET 1 FREE

3990
SAVE €1995 WITH THIS PASS
 
Access to workshops
Access to 2 forum days
Access to evening event
PDF presentations after event

BUY 3 GET 2 FREE

5989
SAVE € 3390 WITH THIS PASS
 
Access to workshops
Access to 2 forum days
Access to evening event
PDF presentations after event

FORUM PASS ONLY

1295
Super Early Bird
YOU JUST SAVED €400
 
Access to 2 forum days
Access to evening event Oct 15th
PDF presentations after event

BUY 2 GET 1 FREE

3390
SAVE €1695 WITH THIS PASS
 
 
Access to 2 forum days
Access to evening event Oct 15th
PDF presentations after event

BUY 3 GET 2 FREE

5085
SAVE € 3390 WITH THIS PASS
 
 
Access to 2 forum days
Access to evening event Oct 15th
PDF presentations after event

PRE FORUM WORKSHOP ONLY

695
Access to pre-forum workshop only

Group discounts are available of > 3 people
Inquire

EXPERT FORUM PASS

2995
15-16 OCT
Access to the 2 forum days
Access to evening event
PDF presentations after event

GROUP RATES

on demand
Group discounts of > 2 people